Showing posts with label Pertuzamab. Show all posts
Showing posts with label Pertuzamab. Show all posts
Wednesday, February 24, 2010
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - abstract
Conclusion: Pertuzumab may add activity to gemcitabine for the treatment of platinum-resistant ovarian cancer. Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic marker.
Subscribe to:
Posts
(
Atom
)
